CS4.3 Ursodeoxycholic acid treatment for HCV patients
نویسندگان
چکیده
منابع مشابه
The ursodeoxycholic acid for the treatment of HCV infections.
UNLABELLED Hepatitis C is a very serious disease. If it is not treated, it leads to chronic hepatitis and cirrhosis in 50% and 20% of cases, respectively. Furthermore, patients with cirrhosis might develop hepatocarcinoma. Interferon seems to be the therapy of choice in the treatment of the disease. However, since the molecule cannot always be used (non-compliant patient; severe side effects; l...
متن کاملUrsodeoxycholic acid
Ursodeoxycholic acid is an epimer of chenodeoxycholic acid (DB06777). It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. [PubChem] Indication: The drug reduces cholesterol absorption and is used to dis...
متن کاملTherapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis.
Primary biliary cirrhosis (PBC) is a chronic cholestatic, progressive inflammatory liver disease with a suspected autoimmunological pathogenesis. The disease is typically diagnosed in women at an age between 30 and 65 years and has a prevalence of up to 1 in 1000 women over the age of 40. The only approved medical therapy for PBC is ursodeoxycholic acid (UDCA) in a recommended dose of 13–15mg/k...
متن کاملUrsodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis.
BACKGROUND Amyloidosis represents a group of different diseases characterized by extracellular accumulation of pathologic fibrillar proteins in various tissues and organs. Severe amyloid deposition in the liver parenchyma has extrahepatic involvement predominantly in the kidney or heart. We evaluated the effect of ursodeoxycholic acid, in four patients with severe hepatic amyloidosis of differe...
متن کاملLong-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
AIMS/BACKGROUND Current therapy for chronic hepatitis C virus (HCV) infection is based on the administration of interferon alpha (IFN) alone or in combination with other anti-viral agents. However, such therapy is effective in only a minority of selected patients. Long-term ursodeoxycholic acid (UDCA) treatment has been reported to improve liver function and structure especially in cholestatic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2011
ISSN: 1201-9712
DOI: 10.1016/s1201-9712(11)60016-7